Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27365962 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2HTTATMALDH1A1 | |
| SCHEMBL64202 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2HTTATMALDH1A1 | |
| SCHEMBL24669979 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2HTTATMALDH1A1 | |
| Hydrochloric Acid SCHEMBL2419232 | 0.82 | USP2 (0.49) | USP2SMN1; SMN2HTTATMALDH1A1 | |
| Lithium SCHEMBL31218220 | 0.82 | USP2 (0.49) | USP2SMN1; SMN2HTTATMALDH1A1 | |
| SCHEMBL2737190 | 0.81 | HRH3 (0.58) | USP2SMN1; SMN2HTTATMALDH1A1 | |
| SCHEMBL1514910 | 0.81 | USP2 (0.47) | USP2SMN1; SMN2HTTATMALDH1A1 | |
| SCHEMBL20399124 | 0.81 | USP2 (0.47) | USP2SMN1; SMN2HTTATMALDH1A1 | |
| SCHEMBL5599546 | 0.80 | USP2 (0.53) | USP2SMN1; SMN2HTTATMALDH1A1 | |
| SCHEMBL18294 | 0.78 | USP2 (0.69) | USP2SMN1; SMN2HTTATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2026-01-29 | — | — | US | disclosed |
| US-12473272-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2025-11-18 | — | — | US | disclosed |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-27 | — | — | US | disclosed |
| US-11897869-B2 | JAK1 selective inhibitors | ASTAZENECA AB (SE) | 2024-02-13 | — | — | US | disclosed |
| EP-4219470-A1 | JAK1 SELECTIVE INHIBITORS | Astrazeneca AB (SE) | 2023-08-02 | — | — | EP | disclosed |
| CN-115925693-A | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3571192-B1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2022-11-30 | — | — | EP | disclosed |
| CN-110461830-B | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA PHARMACEUTICALS LP | 2021-06-24 | — | — | US | disclosed |
| US-10961228-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| WO-2018134213-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473272-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | USP2 2312/4885SMN1; SMN2 3187/4885HTT 3473/4885 |
| US-11897869-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | USP2 2312/4885SMN1; SMN2 3187/4885HTT 3473/4885 |
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | USP2 555/4885SMN1; SMN2 3172/4885HTT 4086/4885 |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | USP2 2312/4885SMN1; SMN2 3187/4885HTT 3473/4885 |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | USP2 2312/4885SMN1; SMN2 3187/4885HTT 3473/4885 |
| US-10961228-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | USP2 2312/4885SMN1; SMN2 3187/4885HTT 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.